Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease

被引：28
|
作者：
Restellini, Sophie [1 ,2 ]
Afif, Waqqas [1 ]
机构：
[1] McGill Univ, Hlth Ctr, Div Gastroenterol, Montreal, PQ H3G 1A4, Canada
[2] Genevas Univ Hosp, Div Gastroenterol & Hepatol, CH-1205 Geneva, Switzerland
来源：
JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 06期
关键词：
therapeutic drug monitoring; biologic; ustekinumab; vedolizumab; tofacitinib; ACTIVE ULCERATIVE-COLITIS; JANUS KINASE INHIBITOR; MAINTENANCE THERAPY; CROHNS-DISEASE; INDUCTION THERAPY; TROUGH CONCENTRATIONS; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; ASSOCIATION; PHARMACOKINETICS;
D O I：
10.3390/jcm10061242
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The goal of therapeutic drug monitoring (TDM) is to optimize anti-TNF (tumor necrosis factor) biologic treatment in patients with inflammatory bowel disease (IBD). Although commercial assays are readily available for both ustekinumab and vedolizumab, the use of TDM with these newer biologic medications is at its infancy. The clinical utility of TDM with non-anti-TNF mechanisms of action is not clear. This review summarizes the latest available data on the pharmacokinetics of newer biologic and oral small molecules and highlights the threshold concentrations that have been associated with improved outcomes in IBD patients.
引用
收藏
页码：1 / 16
页数：15
相关论文
共 50 条
  • [31] Therapeutic drug monitoring in inflammatory bowel disease treatments
    Wang, Meng-Yao
    Zhao, Jing-Wen
    Zheng, Chang-Qing
    Sang, Li-Xuan
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (15) : 1604 - 1607
  • [32] Updates in therapeutic drug monitoring in inflammatory bowel disease
    Lodhia, Nilesh
    Rao, Shanti
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (21) : 2282 - 2290
  • [33] Updates in therapeutic drug monitoring in inflammatory bowel disease
    Nilesh Lodhia
    Shanti Rao
    [J]. World Journal of Gastroenterology, 2022, (21) : 2282 - 2290
  • [34] The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease
    Anbarserry, Doaa
    Mosli, Mahmoud
    Qari, Yousef
    Saadah, Omar
    Bokhary, Rana
    Esmat, Ahmed
    Alsieni, Mohammed
    Shaker, Ahmed
    Elango, Ramu
    Alharthi, Sameer
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [35] Longer Duration of Response With Proactive Therapeutic Drug Monitoring for Infliximab but Not for Vedolizumab Treatment in Patients With Inflammatory Bowel Disease
    Al Yassin, Sarmed
    Spataro, Joseph
    Kang, Le
    Gaidos, Jill
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S359 - S359
  • [36] Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment-TUMMY Study
    Sivridas, Merve
    Creemers, Rob H.
    Wong, Dennis R.
    Boekema, Paul J.
    Romkens, Tessa E. H.
    Gilissen, Lennard P. L.
    van Bodegraven, Adriaan A.
    Loeff, Floris C.
    Rispens, Theo
    Derijks, Luc J. J.
    [J]. PHARMACEUTICS, 2023, 15 (03)
  • [37] The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease
    Doaa Anbarserry
    Mahmoud Mosli
    Yousef Qari
    Omar Saadah
    Rana Bokhary
    Ahmed Esmat
    Mohammed Alsieni
    Ahmed Shaker
    Ramu Elango
    Sameer Alharthi
    [J]. Scientific Reports, 13
  • [38] The role of ustekinumab and vedolizumab in management of extra intestinal manifestations in inflammatory bowel disease
    Katsanos, Konstantinos H.
    Fousekis, Fotios S.
    Armuzzi, Alessandro
    [J]. DIGESTIVE AND LIVER DISEASE, 2023, 55 (02) : 149 - 150
  • [39] The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
    Choi, Myeong Geun
    Ye, Byong Duk
    Yang, Suk-Kyun
    Shim, Tae Sun
    Jo, Kyung-Wook
    Park, Sang Hyoung
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (14)
  • [40] Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
    Lutz, Megan
    Caldera, Freddy
    Schroeder, Katie
    Gazis, Derek
    Crawford, Julie M.
    Long, Millie D.
    Barnes, Edward L.
    [J]. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2023, 14 (11)
12345